Journal
ONCOIMMUNOLOGY
Volume 1, Issue 6, Pages 997-999Publisher
LANDES BIOSCIENCE
DOI: 10.4161/onci.19865
Keywords
BRAF; BRAF mutation; CTLA-4; immunotherapy; immune response; melanoma; pathology; tumor infiltrating lymphocytes; targeted therapy
Categories
Ask authors/readers for more resources
Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
